Study Examines Coffee Consumption and Mortality Risk Post-Heart Attack

Background on Coffee and Cardiovascular Health

A recent study investigated the link between coffee consumption and mortality risk among individuals who have previously experienced a heart attack. While existing research suggests that coffee may lower the risk of cardiovascular disease (CVD), ischemic heart disease (IHD), and all-cause mortality in the general population, the benefits for patient populations remain unclear.

Mixed Results in Previous Research

Previous studies exploring the relationship between coffee intake and mortality in patients with cardiac events have produced inconsistent findings. Some research indicates no effect of coffee consumption, while others suggest a potential reduction in mortality risk.

Prospective Study by Dutch Researchers

To clarify these discrepancies, Dutch researchers conducted a prospective study focusing on both caffeinated and decaffeinated coffee consumption among Dutch patients aged 60 to 80 who had experienced a heart attack, also known as myocardial infarction (MI). The study utilized data from 4,837 men and women who participated in a three-year intervention study on omega-3 fatty acids from 2002 to 2006. Ultimately, 4,365 participants met the inclusion and exclusion criteria for the current analysis.

Data Collection and Participant Demographics

Participants completed food frequency questionnaires detailing their coffee consumption, including frequency, amount, type, and preparation methods over the past month. The researchers calculated total coffee intake in cups and milliliters per day. Additionally, data on sociodemographic factors, lifestyle, and medical history were collected. Mortality data were retrieved from the Dutch National Mortality Registry covering the period from 2002 to 2013. The average age of participants was 69, with nearly 80% being men who had suffered a heart attack approximately four years prior. Most participants were coffee drinkers, with a median intake of about three cups per day.

Findings from the Follow-Up Period

During a seven-year follow-up, there were 945 recorded deaths, including 396 from CVD, 266 from IHD, and 71 from stroke. After adjusting for sociodemographic characteristics (such as age, gender, and education) and other relevant factors (including physical activity, obesity, diabetes, and alcohol use), the researchers found that participants who consumed more coffee (2-4 cups or more than 4 cups daily) had a 20% to 30% lower risk of dying from CVD or IHD compared to those who consumed 0 to 2 cups daily. They also exhibited a 16% to 18% lower risk of death from any cause.

Limitations and Future Research Directions

The researchers could not draw conclusions about coffee consumption’s impact on stroke mortality due to a limited number of cases. Additionally, the results were consistent across both decaffeinated and caffeinated coffee consumption, regardless of additives. Although the study’s prospective design strengthens its findings, it predominantly involved male participants and had few non-coffee drinkers. The study did not differentiate between filtered and unfiltered coffee, although most older individuals in the Netherlands typically consume filtered coffee.

Further investigations are needed to explore coffee consumption’s effects on mortality risk in women, individuals with a history of stroke, and more diverse patient populations.

Conclusion

Published in The American Journal of Clinical Nutrition, the findings suggest that coffee consumption is safe for those who have experienced a prior heart attack, potentially offering protective benefits against mortality risk. Despite the inability to establish the precise mechanisms behind this association, prior research indicates that polyphenols in coffee may enhance vascular function and insulin sensitivity.

Reference

van Dongen, Laura H., et al. “Coffee consumption after myocardial infarction and risk of cardiovascular mortality: a prospective analysis in the Alpha Omega Cohort.” The American Journal of Clinical Nutrition (2017): ajcn153338.